Galapagos « Terug naar discussie overzicht

Analyst reports 2018

220 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 » | Laatste
avantiavanti
4
Credit Suisse 28 juni 2018

PELICAN Disappointment, ABBV Hesitation Raise Questions on Future of CF Franchise
Bijlage:
avantiavanti
4
Berenberg 29 juni 2018

Galapagos (GLPG NA) - Cystic fibrosis collaboration under review

Galapagos (GLPG NA, Buy; PT EUR 112.00)

Galapagos has announced the results of its PELICAN phase II trial in cystic fibrosis, which was evaluating corrector GLPG2737 in combination with double therapy Orkambi (from Vertex Pharmaceuticals). The trial met its primary endpoint of reducing sweat chloride but did not significantly improve lung function (FEV1), a key secondary endpoint, although there was a positive trend showing a 3.4% improvement in FEV1 over placebo. However, the bigger news is that partner Abbvie has decided not to proceed with a second triple-combination trial, bringing into question the future of its collaboration with Galapagos. While the tensions between the two partners have not been a secret recently, this decision increases the risk profile around the whole programme as the parties decide which of them will take the lead.

The PELICAN trial was designed to be a proof of concept evaluating the target exposure levels and efficacy of the corrector GLPG2737. While there was a clear improvement in sweat chloride levels in patients, an improvement in FEV1 of 3.4% over placebo is lower than the 5% improvement generally seen as meaningful. Importantly, the drug was well tolerated, with no serious adverse events and no discontinuations due to adverse events.

PELICAN was part of a broad development programme, with a number of combination trials underway or in planning. The FALCON trial, evaluating the first investigational triple combination (GLPG2451, GLPG2222 and GLPG2737), is due to read out later this year and is progressing as planned. A second triple-combination trial (GLPG3067, GLPG2222 and GLPG2737) is currently in preparation. However, Abbvie has told Galapagos that it does not want to proceed with this specific combination. Abbvie’s decision is most likely due to a combination of the recent PELICAN data as well as the long-standing tension between the two partners. As a result, Galapagos has stated that it is reviewing the future of its collaboration with Abbvie as it is becoming clear that the two cannot continue development together.

Under the current terms, Galapagos is responsible for funding up to phase II development. Abbvie, meanwhile, is responsible for funding phase III development and commercialisation, paying Galapagos up to USD600m in milestones and a royalty of up to 20%. However, both parties are involved in the design and planning of the programme at all stages. There had been rumours that the relationship was strained for some time, contributing to delays in trial starts and disagreements on progress. This is clearly an opportunity for Galapagos to take full control of the programme and develop it internally, potentially finding a new partner down the line. At this stage, the financial implications of a termination are not clear. However, the company has assured us that FY 2018 guidance is unchanged.

The cystic fibrosis programme is currently worth EUR14.7 per share in our EUR112 valuation, risk adjusted to 50%. Clearly, this news creates uncertainty around the programme. However, in recent months several pipeline programmes have progressed into more-advanced trials, jumping up the ranks in relative valuation. GLPG1690 for IPF (idiopathic pulmonary disease) has moved into phase III development, MOR106 for atopic dermatitis has progressed into into phase II development, and most recently GLPG1972 for osteoarthritis progressed into phase II development. Additionally, we have seen strong data for filgotinib this year, the most valuable pipeline programme, in psoriatic arthritis and progress into phase III in ulcerative colitis. Data from FINCH 2, in rheumatoid arthritis, is expected in H2 with FINCH 1 and FINCH 3 expected next year.

Based on an SOTP valuation of the pipeline, our valuation of EUR112 per share offers significant upside, particularly as we receive data from filgotinib’s FINCH 2 and the cystic fibrosis programme triple-combination trials, and the initiations of several clinical trials validate the pipeline.
avantiavanti
4
Jefferies 5 juli 2018

Galapagos (GLPG NA) No Need to Flinch Ahead of FINCH; Should Reassure on Filgotinib's Potential
Bijlage:
avantiavanti
4
Jefferies 5 juli 2018 mbt Gilead/Filgotinib

Gilead Sciences (GILD): Phase III Filgotinib RA Data Coming ... Another Driver for the Turnaround - Buy

Rating BUY
Price Target $95.00
Price $71.33

Key Takeaway
In this report, we dive into GILD's filgotinib program which could have first data in weeks, in our view. Key is comparable efficacy and clean safety, which could differentiate it from other JAKs and be a positive read-through to separate big Phase III UC program ($2B+ market). Together, data for filgotinib in RA and selonsertib in NASH (H1:19) could help grow EPS and PE expansion towards 15x ie $90-95. **Read more inside for key info, charts, etc**

GILD remains our top large-cap idea for a turnaround story and the most under-owned large cap in our coverage universe. We think HCV will move behind us and new drivers such as filgotinib, NASH assets, and even a new HIV drug (capsid) could spark renewed interest in this stock. Q2 and Q3 mark important quarters for GILD given the company appears close to hitting a trough and a U-shaped recovery, which would make it a more ownable story for many generalists. Our call for a turnaround is based on HIV with strong Biktarvy numbers, (2) Yescarta CAR-T continuing to grow sequentially, and (3) HCV sales decline finally troughing (scripts are tracking to -7% Q/Q vs -16% last quarter). And finally Phase III RA data coming to light in 2018-2019 and then big Phase III NASH data in H1:19 could move the stock 10-15%+ towards our PT of $95/share and could contribute meaningfully to GILD's EPS growth, driving multiple expansion towards 15x, which on $6 EPS is $90+ (~25-35% upside from current ~$70).

Filgotinib (partnered with GLPG - Buy, see separate report by analyst P. Welford today) represents a $2-3B+ franchise that we expect will attract growing attention - first RA study in biologic failures (FINCH-2) is expected imminently. If positive, filgotinib could be differentiated from other oral JAKs. Consensus models peak $2.5B+ for PFE's Xeljanz and $2B+ for LLY's Olumiant, even though both drugs have black box warnings and LLY was approved only for lower 2mg dose...we think filgotinib can be differentiated as its JAK1 selectivity is more likely to: (1) not decrease platelets (thus pot'l less DVT risk like others), (2) not decrease hemoglobin levels, NK cells, etc and pot'l less risk of infections. Filgotinib could be "best in class" although 4th to market - and we acknowledge rebating will also be key here in the competitive market, as we note the Street currently already appears unclear about how it will play out, hence not enough credit yet for the franchise. For efficacy, GILD may not have details in press releases other than disclosing/hitting the 12-wk primary endpoint of ACR20, which we view pbo-adjusted 20-25% for low dose and 25-30% for high dose as positive.
avantiavanti
14
Mooi report van DeGroof Petercam 19 juli 2018

Galapagos CrackerJAK

Best-in-class potential ? Our interactions with key opinion leaders in the field taught us that targeted small molecule inhibitors are expected to transform the treatment paradigm in the field of autoimmune disease, with filgotinib potentially being a best-in-class JAK inhibitor. ? Following the commercially available Xeljanz and Olumiant, the next wave of JAK inhibitors, upadacitinib and filgotinib, have been developed to be more selective for JAK1 and thus to show a superior safety profile. To date, filgotinib has been able to show the most favourable data concerning adverse events that characterize this class of therapies. ? In 2H18, Galapagos and partner Gilead aim to report topline results of the Phase III FINCH-2 study in rheumatoid arthritis. Gilead progressed fast through recruitment, bringing ahead the readout of FINCH-1 and 3 to 1H19.

Multiple shots at goal ? Besides the progress with filgotinib, the past year yielded a wealth of results with remarkable data from Galapagos’ proprietary idiopathic pulmonary fibrosis program, which moved into Phase III, as well as from the atopic dermatitis and osteoarthritis trials. ? On the other hand, the cystic fibrosis program experienced a significant setback when the PELICAN trial failed to show a strong effect of ‘2737 on top of Orkambi. As this component is part of the first triple combination in the clinic, the chances of success for Galapagos in CF are becoming slim.

Lead asset nearing Phase III readout ? The first Phase III results in rheumatoid arthritis will definitely move the needle for Galapagos. The FINCH-2 study targets the most difficult to treat RA patients. Positive results will thus further de-risk the larger FINCH-1/3 studies. ? The upcoming news flow will provide multiple value inflection points through which significant upside could materialize in the coming quarters. ? Incorporating feedback from the medical community, we have taken a more bullish stance on the future of JAK inhibitors in the field of autoimmune disease in general and the best-in-class potential of filgotinib specifically. Adjusting our assumptions to reflect this item, we raise our TP to EUR 110 from EUR 99.
Bijlage:
avantiavanti
12
aossa
0
In een lijvige update over de groep verhoogt Degroof Petercam het advies van 99 naar 110 euro. 'Op dit ogenblik vertegenwoordigt het eczeemonderdeel slechts 3 euro van ons koersdoel van 110 euro, maar het opwaarts potentieel is significant', merkt analiste Stéphanie Put op.

'De deal met Novartis onderstreept nog eens de waarde van het onderzoeksplatform van Galapagos. De komende maanden verwachten we ook een belangrijke nieuwsflow, met vooral de eerste resultaten van de derde en laatste klinische testfase voor filgotinib bij de behandeling van reumatoïde artritis'. Recent testresultaten onderstreepten trouwens dat filgotinib intussen veel méér is dan een 'potentieel reumamiddel'.

Het reuma-onderzoek waardeert Put met potentiële Europese en Amerikaanse piekverkopen van 4 miljard euro per jaar tegen 2026 nu op 39 euro per aandeel. Maar daar komen nog - alleen voor filgotinib - de lopende onderzoeken bij rond de ziekte van Crohn (13 euro per aandeel) en colitis ulcerosa (9 euro per aandeel). Daar komt 6 euro per aandeel bij voor andere onderzoeken met filgotinib, onder meer rond psoriasis artritis.

Bron: De Tijd..be
avantiavanti
7
Barclays 30 juli 2018

Galapagos

Scopes was right to teach Darwin


Stock Rating: Overweight (from N/A)
Industry View: Positive
Price Target: EUR 130.00 (from N/A)
Price (26-Jul-2018): EUR 95.72
Potential Upside/Downside: +35.8%
Tickers: GLPG.NA / GLPG.AS

The development of monoclonal antibodies over the last two decades has revolutionized the treatment of inflammatory autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. Whereas the prior standard of care employed legacy immunosuppressive drugs causing a myriad of safety concerns, these new biologics can oftentimes induce complete remission in patients suffering from these lifelong and frequently debilitating diseases. However, these are far from miracle drugs. In some disease states, secondary loss of response occurs in up to 50% of patients annually and the drugs are administered via inconvenient infusion or uncomfortable injection. Thus, unmet medical need remains high.

We believe we are at the outset of a new revolution in the treatment of autoimmune diseases that will be led by an emerging class, the Janus kinase (JAK) inhibitors. These oral drugs are inherently more convenient for patients and have demonstrated superior efficacy to the current market leader (Abbvie's Humira) in clinical trials (given that Cimzia competes directly with Humira, this reaffirms our negative view on UCB, Bime no salve for rheumatic pains (28/02/18)). However, we believe all JAKs are not created equal. It is our contention that filgotinib, developed by Belgian biotech company Galapagos, with its selectivity for JAK1 (more detail on that inside) is a best-in-class asset and with a powerhouse partner in Gilead, we expect a rapid sales ramp; we forecast $2.1bn of risk-adjusted revenues in 2025, 15% ahead of Gilead sell-side consensus. Whilst we concede that this is a consensus call, our deep dive on filgotinib's mechanism of action has us happily drinking the Kool-Aid and we initiate coverage at Overweight, with an NPV-derived PT of €130.

Platform pipeline on the verge of validation: Filgotinib was generated with Galapagos's proprietary drug discovery platform, which is on the verge of being validated as we will soon see pivotal data not only for filgotinib, but also for IPF asset, GLPG 1690. Whilst formerly a significant component to the GLPG story, we currently place very little emphasis on its programme in cystic fibrosis.

Valuation & risks: Given that we do not forecast GLPG to become profitable until 2022, we use an NPV-derived price target of €130/share, using a 10% WACC and -1% t. growth rate. Near-term risks include: failure of filgotinib in FINCH 2 in RA in 3Q18.
[verwijderd]
0
Kan iemand mij uitleggen wat Barclays bedoeld met de laatste zin van hun advies: Near-term risks include: failure of filgotinib in FINCH 2 in RA in 3Q18.

Betekend dit dat ze een prijs van 130 aanhouden waarbij ze eventuele slechte resultaten van RA fase 3 hebben ingecalculeerd. Dus wanneer de resultaten goed zijn en het risico op slechte resultaten wegvalt het koersdoel nog significant gaat stijgen.

Wat eigenlijk betekent dat dit een koersdoel is tot aan de fase 3 resultaten van het RA onderzoek.
Beurskingpin
0
quote:

lmr schreef op 31 juli 2018 11:17:

Kan iemand mij uitleggen wat Barclays bedoeld met de laatste zin van hun advies: Near-term risks include: failure of filgotinib in FINCH 2 in RA in 3Q18.

Betekend dit dat ze een prijs van 130 aanhouden waarbij ze eventuele slechte resultaten van RA fase 3 hebben ingecalculeerd. Dus wanneer de resultaten goed zijn en het risico op slechte resultaten wegvalt het koersdoel nog significant gaat stijgen.

Wat eigenlijk betekent dat dit een koersdoel is tot aan de fase 3 resultaten van het RA onderzoek.
Het betekent als finch 2 faalt hun koersdoel 40 zal zijn.. lol
[verwijderd]
0
twitter.com/tgtxdough/status/10242428...

Slechts 5% upside bij positieve resultaten bij Finch2 volgens MS, is dat niet ontzettend conservatief? Iemand inzicht gehad in het rapport waarin dit staat? Ben wel benieuwd naar de verdere motivatie...
NielsjeB
0
quote:

aossa schreef op 31 juli 2018 19:10:

Er staat +20%
MS filgotinib see a positive result (efficacy similar to upadacitinib, but a clean signal of DVT/PE, hemoglobin&platelets)as driving GILD up low-single digit % & $GLPG ~5% while a surprising safety signal or efficacy well below upadacitinib driving down $GILD ~3-5% and GLPG 20%+)

Ik weet niet hoe accuraat deze quote uit het rapport is, maar er wordt alleen over similar efficacy gesproken (5% up in dat geval) of tegenvallende efficacy of safety signal (20%+ down in dat geval).

Het scenario waar efficacy hoger is dan upa doet MS blijkbaar geen uitspraak over. Wij hopen dan natuurlijk ook 20%+, maar dat is voor onze rekening.

Iemand het rapport waar deze quote uit komt?
avantiavanti
5

Jefferies 3 augustus 2018

Galapagos (GLPG NA): 2018 Burn Outlook Narrowed as Expected; Key Pipeline Catalysts On-track

Rating BUY

Price Target €115.00

Price €92.22

Key Takeaway

1H financials are not material with higher Revenues offset by greater OpEx vs. consensus. We await the 1pm UK/8am EST call for possible R&D updates, notably on the status of the AbbVie CF partnership. Key upcoming catalyst is the filgotinib FINCH-2 data. We are optimistic filgotinib efficacy will be in line with other JAKi's, but believe its potentially superior safety profile could be a key differentiator, driving uptake despite likely being fourth to market.



Bijlage:
avantiavanti
7

DeGroof Petercam 3 augustus 2018

Galapagos (Buy) - On track to deliver important milestones in the coming months (EUR 92 / TP EUR 110)

Facts – FY18 operational cash burn guidance lowered to EUR 180-200m

Galapagos reported its 1H18 financial results. Revenues and other income came in higher than expected at EUR 101.9m versus our anticipated EUR 91.4m (Css. EUR 84.5m). Revenues increased to EUR 87.6m (from EUR 60.9m 1H17) as a result of increased revenue recognition of upfront payments (related to the Gilead collaboration) and due to the adoption of IFRS15.

Operating expenses increased YoY, landing at EUR 167.6m (DPe EUR 157m; Css EUR 149m), with R&D EUR 151.4m and SG&A EUR 16.2m. This increase in OpEx is mainly attributed to an increase in subcontracting costs primarily relating to the filgotinib and IPF (GLPG1690) programs, as expected. This leads to an operating loss of EUR 65.8m. The company realized a net loss of EUR 59.1m.

Cash & cash equivalents came in at EUR 1,066.8m (DPe EUR 1,059.5m; Css EUR 1,061.7m)

On the development pipeline, the company provides the following outlook for 2018:
-Top line results of the filgotinib trials FINCH 2 (Phase III, rheumatoid arthritis) and TORTUGA (Phase II, ankylosing spondylitis) in 3Q18.

-Interim readout of the FALCON trial in cystic fibrosis in 3Q18.

-Start dosing in the Phase III ISABELA trial with GLPG1690 (idiopathic pulmonary fibrosis), as well as Phase II trials with GLPG1205 (IPF; PINTA) and GLPG1972 (osteoarthritis; ROCCELLA).

On the outlook for FY18, management lowers its guidance for operational cash burn from EUR 220-240m to EUR 180-200m as a result of the recently announced collaboration agreement with Novartis on MOR106.

Our view – Key upcoming results of lead product

Galapagos continues with a strong cash position to further fuel its discovery platform while starting the foundations of a commercial organization. A positive is that the cash burn will be slightly lower than previously guided thanks to the licensing of MOR106 to Novartis. Cash burn is now guided to be in the EUR 180-200m range (vs. EUR 220-240m previously).

The coming quarters will be news flow rich, with the most important item being results of the filgotinib trials. The Phase III results in rheumatoid arthritis (FINCH 2) will lead the way of the stream of trial readouts of Galapagos’ JAK inhibitor (we refer to our recent report ‘CrackerJAK’ for detailed information). Subsequent to the strong results in psoriatic arthritis, the second proof-of-concept trial to read out this year will be in ankylosing spondylitis.

Following the setback with GLPG2737 in the cystic fibrosis PELICAN trial, expectations for the ongoing triple combination FALCON trial are very low. Any positive news from the trial could provide further upside, though we attributed only 10% probability of success to the program at this stage.

Investment conclusion
The upcoming news flow will provide multiple value inflection points through which significant upside could materialize in the coming quarters, with the most important milestone being the FINCH-2 readout. Filgotinib represents the main part of our sum-of-the-parts valuation (EUR 70 of our EUR 110 TP). In our view, the market has yet to incorporate the full impact of JAK inhibitors in the autoimmune space as well as the potential of additional indications for filgotinib. We see Galapagos as our key play for year end, as we anticipate a further rerating the closer we move to the Phase III readout of filgotinib. We reiterate our Buy recommendation.
avantiavanti
6
Goldman Sachs

Galapagos NV (GLPG.AS): Downgrade from Buy to Neutral; balanced risk-reward into upcoming catalysts



9 August 2018 | 9:33PM BST

Given Galapagos’ recent outperformance vs. the SXDP (+10%), especially post the disappointment on the Cystic Fibrosis update on June 28, we see a more balanced risk-reward going into the mid- to late-stage readouts for filgotinib’s FINCH2 trial in rheumatoid arthritis (3Q18) and TORTUGA trial in ankylosing spondylitis (3Q18).

We continue to believe that Galapagos’ IPF assets if successful could provide meaningful value creation in the long term, however the readouts for these programs are unlikely until the 2020-21 timeframe at the earliest.

As a result, we downgrade to Neutral, from Buy. Since adding to the Buy List on October 18, 2016, the shares are +59.8% vs. the FT World Europe +13.6%. This share outperformance has been largely driven by further pipeline advancements. We see a fundamental DCF-based value of €92 per share and incorporate an M&A component of €4 per share, which assumes an M&A valuation of €120/share.

There are no fundamental changes to our view on any of the assets or indeed Galapagos' long-term attractiveness as an M&A candidate.

Risks: Upside risk: (1) superior efficacy/cleaner safety data for filgotinib vs. JAK class of inhibitors (2) trial success of IPF assets; Downside risk: (1) negative clinical trial outcome from the filgotinib trials (2) ability to recruit patients in the IPF trials (3) any announcement on partnership discontinuation.
avantiavanti
9
Nomura 22 augustus 2018

Galapagos NV - Filgo Ph3 FINCH2 Data Soon: Our Expectations
Expecting Similar Efficacy in RA as Upa, but with a Superior Safety Profile


Deel 1
Bijlage:
220 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 17 apr 2024 17:39
Koers 27,380
Verschil -0,320 (-1,16%)
Hoog 27,680
Laag 27,160
Volume 104.556
Volume gemiddeld 80.458
Volume gisteren 82.849

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront